Standard of Care Durvalumab for Limited-Stage SCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBAAnne Chiang, MD, PhD

Panelists discuss how the ADRIATIC trial investigating durvalumab in limited-stage small cell lung cancer (SCLC) has shown promising results, potentially addressing unmet needs in this patient population, and consider its potential impact on treatment algorithms and its possible emergence as a new standard of care if approved for this indication.

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

EP: 3.Immunotherapies for Extensive-Stage SCLC

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

Now Viewing

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

Now that we’ve discussed extensive-stage small cell lung cancer (SCLC), let’s move into limited stage. Durvalumab has also demonstrated encouraging results in patients with limited-stage SCLC in the ADRIATIC trial. Can you discuss the trial design and the key results that were seen?

How do you see durvalumab fitting into treatment algorithms if approved? Do you see it as a potential new standard of care for patients with limited-stage SCLC?

What are the unmet needs that the ADRIATIC trial addresses for patients with limited-stage SCLC?